Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Researcher

Alessandro Guedes De Amorim

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 8, 2026 · JOURNAL ARTICLE

THE RELATIONSHIP BETWEEN THE IMMUNOTHERAPEUTIC PEMBROLIZUMAB AND THE ONSET OF TOXIC EPIDERMAL NECROLYSIS (TEN) AS AN ADVERSE EFFECT

Lumen Et Virtus

A single case report describing TEN onset with pembrolizumab; establishes occurrence but lacks comparative data, denominators, or mechanistic evidence to support stronger claims.

PreliminaryBruno Stéfano Lima Dallago Fernanda Lima Guedes Pedro de Paiva Rosa Vaz

Reported

Patient age48 years

Typical time to TEN onsettwo to six weeks after starting treatment

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support